Information Provided By:
Fly News Breaks for December 3, 2019
QURE
Dec 3, 2019 | 06:26 EDT
Goldman Sachs analyst Salveen Richter initiated coverage of uniQure with a Buy rating and $98 price target. uniQure is a clinical-stage gene therapy company targeting liver and central nervous system disorders and developed the first commercial gene therapy, Glybera, Richter tells investors in a research note. The analyst is positive on the company's lead program AMT-061 in hemophilia B. Further, he views the Huntington's disease program as the next key value driver with first safety/biomarker data in 2020.
News For QURE From the Last 2 Days
There are no results for your query QURE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.